Summary

Overview
The global liposomal doxorubicin market reached US$ 1.33 billion in 2024 and is expected to reach US$ 2.23 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2025-2033.
Liposomal doxorubicin is a specialized formulation of the chemotherapy drug doxorubicin, encapsulated within pegylated liposomes. This innovative delivery system enhances the drug's efficacy by prolonging its circulation time in the bloodstream and targeting cancer cells more effectively while reducing systemic toxicity.
The liposomal doxorubicin market is experiencing significant growth, driven by an increasing global cancer prevalence and advancements in drug delivery technologies. Moreover, the approval of generic versions of liposomal doxorubicin has expanded access to this vital treatment which further drives the market growth.
Market Dynamics: Drivers & Restraints
Increasing prevalence of cancer
The increasing prevalence of cancer is expected to significantly drive the liposomal doxorubicin market. As cancer remains a leading cause of mortality worldwide, with millions of new cases diagnosed annually, the demand for effective treatment options is surging. Increasing cancers such as ovarian cancer and AIDS-related Kaposi sarcoma, are expected to drive the growth of the liposomal doxorubicin market significantly. For instance, according to the American Cancer Society in 2025, about 20,890 women are expected to receive a new diagnosis of ovarian cancer.
As these cancers become more common, the demand for effective treatment options like liposomal doxorubicin, which offers targeted therapy with effectiveness, is expected to increase. This growth is further supported by advancements in drug delivery systems and increased awareness of cancer therapies, as well as ongoing research into new applications for liposomal doxorubicin.
Side effects associated with doxorubicin
The liposomal doxorubicin market is anticipated to encounter obstacles due to the side effects associated with its administration, which may negatively impact patient adherence and overall treatment effectiveness. Notable side effects include hand-foot syndrome, mucositis, and hematological complications such as anemia and neutropenia, all of which can significantly diminish patients' quality of life and lead to discontinuation of therapy. These adverse effects may discourage healthcare professionals from prescribing liposomal doxorubicin or prompt patients to explore alternative treatment options, thereby constraining market growth.
Segment Analysis
The global liposomal doxorubicin market is segmented based on drug form, application, distribution channel, and region.
Drug Form:
Doxorubicin injection is expected to dominate the global liposomal doxorubicin market share
Doxorubicin injection is expected to dominate the liposomal doxorubicin market. This dominance is attributed to several driving factors. The evolution of drug delivery systems has significantly enhanced the efficacy and safety profiles of doxorubicin injections, particularly through innovations like liposomal formulations that encapsulate the drug in lipid spheres. This encapsulation improves targeted delivery to cancer cells while minimizing systemic toxicity, making it a preferred option among oncologists.
Additionally, the rising prevalence of various cancers, including breast and ovarian cancers, has increased the demand for effective treatment options. The convenience of doxorubicin injections, which allow for immediate preparation and administration, further supports their growth in clinical settings. Market players are introducing innovative doxorubicin injections which are further driving the segment’s growth. For instance, in August 2024, Lupin Limited launched Doxorubicin Hydrochloride Liposome Injection in two formulations: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials in the United States. This development follows the approval of the Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA) for its alliance partner, ForDoz Pharma Corporation, USA.
As healthcare providers increasingly favor intravenous therapies for their rapid therapeutic effects, the doxorubicin injection segment is expected to maintain robust growth in the liposomal doxorubicin market moving forward.
Geographical Analysis
North America is expected to hold a significant position in the global liposomal doxorubicin market share
North America is expected to dominate the liposomal doxorubicin market due to several key factors. The region’s market growth is driven primarily by the high prevalence of cancer, particularly breast and ovarian cancers, which necessitates effective treatment options like liposomal doxorubicin. Breast cancer is one of the most common cancers among U.S. individuals. For instance, the American Cancer Society estimates that about 316,950 new cases of invasive breast cancer will be diagnosed in women in 2025. This increase in serious cancers is expected to increase the demand for liposomal doxorubicin.
Additionally, significant investments in oncology research and development foster an environment conducive to the advancement of liposomal drug formulations. The presence of major pharmaceutical companies and ongoing clinical trials further solidifies North America's dominance in the liposomal doxorubicin market. Furthermore, the region benefits from a strong regulatory framework that encourages the adoption of new therapies, enhancing patient safety and treatment efficacy. Overall, these factors are expected to propel North America's market growth, making it a critical hub for liposomal doxorubicin therapies in the coming years.
Competitive Landscape
The major global players in the liposomal doxorubicin market include Getwell Pharma, Encapsula NanoSciences, Lupin, Baxter, Pfizer Inc., Aark Pharmaceuticals, MEDISUS PHARMA, JoinHub Pharma, Aetos Pharma Private Limited and S. G. Biopharm Pvt. Ltd. among others.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Liposomal Doxorubicin Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

• Supply Chain: Distribution and Supply Chain Managers.

• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

• Academic & Research: Academic Institutions.

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Form
3.2. Snippet by Application
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of cancer
4.1.2. Restraints
4.1.2.1. Side effects associated with Doxorubicin
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Drug Form
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Form
6.1.2. Market Attractiveness Index, By Drug Form
6.2. Lyophilized Powder*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Doxorubicin Injection
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Breast Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Ovarian Cancer
7.4. Leukemia
7.5. Multiple Myeloma
7.6. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Form
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. Getwell Pharma*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. Encapsula NanoSciences
11.3. Lupin
11.4. Baxter
11.5. Pfizer Inc.
11.6. Sun Pharmaceutical Industries Ltd
11.7. MEDISUS PHARMA
11.8. JoinHub Pharma
11.9. Aetos Pharma Private Limited
11.10. S. G. Biopharm Pvt. Ltd.
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us